Riociguat (trade name Adempas) is a novel drug (by Bayer) that is a stimulator of soluble guanylate cyclase (sGC). Clinical trials have looked at riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of a novel class of sGC stimulators.

CAS：625115-55-1
中文别名：N-[4,6-二氨基-2-[1-[(2-氟苯基)甲基]-1H-吡唑并[3,4-B]吡啶-3-基]-5-嘧啶基]-N-甲基氨基甲酸甲酯;利奥西呱;
英文别名：Riociguat (JAN/INN);methyl N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-N-methylcarbamate;N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester;Riociguat;Methyl N-(4,6-diamino-2-{1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-b)pyridin-3-yl}pyrimidin-5-yl)-N-methylcarbamate;BAY 63-2521;UNII-RU3FE2Y4XI;Adempas;
分子式：C20H19FN8O2
分子量：422.416
精确质量：422.162
Psa：138.8
Logp：2.954

MDL号：MFCD19443708

密度：1.51g/cm3
沸点：567.202ºC at 760 mmHg
闪点：296.833ºC